James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Fitbit Inc: FIT Is a Roll of the Dice With Fraud Suit Looming

Fitbit stock has a tough, expensive choice to make, and either way, there's still the small matter that its heart-rate monitor watches don't seem to work.

Why Best Buy Co Inc (BBY), Fitbit Inc (FIT) and Newmont Mining Corp (NEM) Are 3 of Today’s Worst Stocks

Best Buy (BBY), Fitbit (FIT) and Newmont Mining (NEM) couldn't win for losing on Tuesday.

HP Inc: HPQ Stock Remains on the Fence

HP (HPQ) continues to tease investors. This old name may have some new blood after all, if a few things fall into place.

AAPL Stock – Buy Apple Inc., But Not on the Rumors

The news is apt to drive Apple stock higher in the short run, but don't be shocked if we hear the opposite again in the near future.

Why Petroleo Brasileiro SA Petrobras (ADR) (PBR), Sarepta Therapeutics Inc (SRPT) and Valeant Pharmaceuticals Intl Inc (VRX) Are 3 of Today’s Worst Stocks

Owners of Petrobras (PBR), Sarepta Therapeutics (SRPT) and Valeant Pharmaceuticals (VRX) wished on Monday that the weekend had lasted one more day.